Navigation Links
Onset Dermatologics Launches HylatopicPlus-Aurstat™ Kit
Date:2/22/2011

CUMBERLAND, R.I., Feb. 22, 2011 /PRNewswire/ -- Onset Dermatologics, a PreCision Dermatology company and a leader in developing and commercializing novel, prescription products for improving skin health, today announced the launch of the HylatopicPlus-Aurstat™ Kit.  The kit provides two products within one package: HylatopicPlus™ Emollient Foam indicated to manage and relieve burning, itching and pain that can accompany skin dermatoses such as atopic dermatitis (eczema) and Aurstat™ Skin & Wound HydroGel, which is used to relieve skin irritation, minor abrasions and lacerations — and also can be used on intact skin.  

"We believe that the newly launched HylatopicPlus-Aurstat™ Kit provides physicians and patients greater convenience when skin barrier dysfunction and S. aureus colonization are present in the same patient," said Doug Abel, General Manager of Onset Dermatologics.  "The kit provides two therapies in one prescription for a single co-pay, which may improve patient adherence to physician instructions and thus, result in improved clinical outcomes."

HylatopicPlus™ Emollient Foam is formulated to rapidly hydrate the stratum corneum (the top layer of the epidermis) and provide a semi-permeable barrier that protects against irritants and excessive water loss through the skin. HylatopicPlus™ incorporates hyaluronic acid to deliver a blend of physiologic lipids, including ceramide, to restore healthy barrier function. HylatopicPlus™ has been clinically proven to improve the symptoms of atopic dermatitis.

Aurstat™ HydroGel is intended for over-the-counter use on minor skin abrasions and lacerations — and for use on intact skin. Aurstat™ contains a unique shelf-stable formulation of hypochlorous acid in hydrogel form. In a laboratory setting, Aurstat™ killed 99.99% of Staphylococcus aureus (S. aureus) within 30 seconds post-applic
'/>"/>

SOURCE Onset Dermatologics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Treatment for Prescription Drug Addiction and Painkiller Abuse has Risen Sharply Since Onset of Financial Crisis, Reflecting Uncertainty About Economy
2. First Patient Enrolled in Multi-Center Clinical Trial of the CorMatrix® ECM® for Pericardial Closure to Reduce the Incidence of New Onset Postoperative Atrial Fibrillation
3. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
4. Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa®
5. Depression and Cognitive Disorders: at the Onset of Alzheimers Disease
6. CorMatrix Receives FDA IDE Approval to Begin Prospective, Randomized Evaluation of New Onset Postoperative Atrial Fibrillation in Subjects Receiving the CorMatrix® ECM™ for Pericardial Closure
7. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
8. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
9. FDA Approves New Treatment for Late-Onset Pompe Disease
10. Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects
11. New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... 7 de julio de 2015 Sequent ... privada centrada en el desarrollo de dispositivos innovadores ... anunciado hoy que R. Michael Kleine ... Kleine cuenta con más de 25 ... dispositivos médicos y la sanidad. Ha gestionado con ...
(Date:7/7/2015)... , July 7, 2015 According to ... Method (Manual, Automated), Product (Consumables, Instrument), Application (Aerobic, Anaerobic, Yeast/ ... Research Institute) - Forecast to 2019", published by MarketsandMarkets, The ... Million by 2019 from $2,750.2 Million in 2014 at a ... 1 78 ma rket data ...
(Date:7/7/2015)... Accelovance, Inc. (Accelovance), a global contract ... General Medicine announced the completion of enrollment and ... Therapeutics, Inc. for the Phase 3 trial of ... SUSTOL® (granisetron injection, extended release) as part of ... receptor antagonist fosaprepitant and IV corticosteroid dexamethasone ...
Breaking Medicine Technology:Sequent Medical nombra a Mike Kleine a su junta directiva 2Sequent Medical nombra a Mike Kleine a su junta directiva 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 2Blood Culture Tests Market Worth $3,893.5 Million by 2019 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 4Accelovance Completes Trial Enrollment and Delivery of Clinical Data for Heron Therapeutics' Phase 3 Trial 2
... WIRE)--May 15, 2007 - Synthetic Blood,International, Inc. ... analysis of its Phase IIa study with ... line with preliminary,study results announced in December ... of increasing patients' oxygen,tension levels compared with ...
... WIRE)--May 17, 2007 - Salix,Pharmaceuticals, Ltd. (NASDAQ:SLXP) today ... the Company's products,will be presented at Digestive Disease ... Digestive Disease Week is considered the,largest and most ... Every year it attracts more than 16,000 physicians,researchers ...
Cached Medicine Technology:Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 2Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 2Salix Pharmaceuticals Previews Digestive Disease Week 2007 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 4Salix Pharmaceuticals Previews Digestive Disease Week 2007 5
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... Times highlights rumors about possible facial rejuvenation that have emerged about Hillary Clinton. ... U.S. Secretary of State looks more youthful than she has in some time ...
(Date:7/7/2015)... ... , ... Greatist today announced the acquisition of Blood, Sweat ... most fun activities to do with friends. , The acquisition of BSC strengthens Greatist’s ... for events, e-commerce, and brand partnerships. , “I’ve been a huge fan of Blood, ...
(Date:7/7/2015)... ... July 07, 2015 , ... Illinois cannabis cultivation centers ... to permit holders. The Medical Cannabis Alliance of Illinois’ (MCAI) board and its ... are committed to making sure patients have access to cannabis as a viable ...
(Date:7/7/2015)... ... ... the end of June Pacific Prime Renewals team in Hong Kong announced that they ... Renewals Manager, Danielle Cotton, aims to not only reduce but eventually eliminate the use of ... send anything between 300 and 600 pieces of paper per month. Not to mention A4 ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... enhance the experience for its patient community using its IDF ePHR, an electronic ... with primary immunodeficiency diseases (PI) to easily track their health information, including symptoms, ...
Breaking Medicine News(10 mins):Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 2Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 3Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:Cannabis Growers and Dispensaries Form Medical Cannabis Alliance of Illinois 2Health News:Pacific Prime Hong Kong Renewals Team Starts Push to go Green 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3
... 6 Osteotech, Inc.,(Nasdaq: OSTE ) announced today ... million from third quarter 2006 revenue of $23.4,million. Revenue ... $17.6 million for the three months ended September 30,2007 ... same segments for the,third quarter of 2006. Gross margin ...
... Thursday, November 8,2007, at 8:30 a.m. Eastern/2:30 p.m. Central ... CTIC and MTAX: CTIC),management team will host ... quarter achievements and financial results. Conference Call ... a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time ...
... Nov. 6 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... September 30, 2007. For the third quarter of 2007, ... share, compared to a net loss of $11.4 million, or,$0.46 ... shares,outstanding for the third quarters of 2007 and 2006 were ...
... - Elsevier Signs Agreement With Bayer HealthCare ... healthcare company, Bayer,HealthCare AG, headquartered in Leverkusen, Germany, ... in electronic format for,the first time, EMBASE Classic ... Excerpta Medica Abstract Journals published between 1947 and,1973. ...
... NASDAQ: CRME TSX: COM, VANCOUVER, Nov. 5 /PRNewswire-FirstCall/ ... announced that Bob Rieder, Chairman and,Chief Executive Officer, will ... Annual Healthcare Conference in New York at 1:20pm Eastern,Time ... A live webcast of Mr. Rieder,s presentation can be ...
... Nov. 5 StatSure Diagnostic,Systems, Inc. (OTC Bulletin ... Drug Administration ("FDA"), through its Center for Devices ... Clinical Laboratory,Improvements Amendments of 1988 ("CLIA") for an ... technology. The HIV 1/2 product,is marketed and distributed ...
Cached Medicine News:Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 2Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 3Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 4Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 5Health News:Rigel Announces Third Quarter 2007 Financial Results 2Health News:Rigel Announces Third Quarter 2007 Financial Results 3Health News:Rigel Announces Third Quarter 2007 Financial Results 4Health News:EMBASE Classic Makes Inroads into Pharmaceutical Industry 2Health News:EMBASE Classic Makes Inroads into Pharmaceutical Industry 3Health News:Cardiome to Present at CIBC Conference 2Health News:Cardiome to Present at CIBC Conference 3Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 2Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: